ccr7 polyclonal antibody Search Results


bs 1305r  (Bioss)
94
Bioss bs 1305r
Bs 1305r, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bs 1305r/product/Bioss
Average 94 stars, based on 1 article reviews
bs 1305r - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
ccr7 antibody  (Bio-Techne corporation)
93
Bio-Techne corporation ccr7 antibody
Ccr7 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccr7 antibody/product/Bio-Techne corporation
Average 93 stars, based on 1 article reviews
ccr7 antibody - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
rabbit anti ccr7 polyclonal antibody  (OriGene)
90
OriGene rabbit anti ccr7 polyclonal antibody
Impaired chemotaxis of IL-6Rα KO BMDCs and its restoration by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. BMDCs were isolated from heterozygous (hetero) and IL-6Rα KO mice. A , Immunofluorescence of IL-6Rα in heterozygous (a) and IL-6Rα KO BMDCs (b) confirming the lack of IL-6Rα in KO BMDCs. B , Collagen-coated, modified Boyden chamber chemotaxis assays of heterozygous (hetero), IL-6Rα KO, and IL-6Rα KO in the presence of sIL-6Rα and IL-6 (KO+sIL-6R/IL-6). Note that KO BMDCs show reduced chemotaxis, which was rescued by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. C & D , IL-6Rα KO did not alter surface expression of <t>CCR7.</t> Immunofluorescence (C) showing similar levels of surface CCR7 in heterozygous (a) and IL-6Rα KO BMDCs (b). Flow cytometry analyses (D) confirming that IL-6Rα KO did not affect the levels of CCR7 surface expression. After CD86-positive heterozygous (a) and IL-6Rα KO (b) BMDCs were gated, the levels of CCR7 surface expression were examined in histogram (c).
Rabbit Anti Ccr7 Polyclonal Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti ccr7 polyclonal antibody/product/OriGene
Average 90 stars, based on 1 article reviews
rabbit anti ccr7 polyclonal antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ccr7/cd197 polyclonal antibody, alexa fluor 647 conjugated  (Bioss)
90
Bioss ccr7/cd197 polyclonal antibody, alexa fluor 647 conjugated
Impaired chemotaxis of IL-6Rα KO BMDCs and its restoration by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. BMDCs were isolated from heterozygous (hetero) and IL-6Rα KO mice. A , Immunofluorescence of IL-6Rα in heterozygous (a) and IL-6Rα KO BMDCs (b) confirming the lack of IL-6Rα in KO BMDCs. B , Collagen-coated, modified Boyden chamber chemotaxis assays of heterozygous (hetero), IL-6Rα KO, and IL-6Rα KO in the presence of sIL-6Rα and IL-6 (KO+sIL-6R/IL-6). Note that KO BMDCs show reduced chemotaxis, which was rescued by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. C & D , IL-6Rα KO did not alter surface expression of <t>CCR7.</t> Immunofluorescence (C) showing similar levels of surface CCR7 in heterozygous (a) and IL-6Rα KO BMDCs (b). Flow cytometry analyses (D) confirming that IL-6Rα KO did not affect the levels of CCR7 surface expression. After CD86-positive heterozygous (a) and IL-6Rα KO (b) BMDCs were gated, the levels of CCR7 surface expression were examined in histogram (c).
Ccr7/Cd197 Polyclonal Antibody, Alexa Fluor 647 Conjugated, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccr7/cd197 polyclonal antibody, alexa fluor 647 conjugated/product/Bioss
Average 90 stars, based on 1 article reviews
ccr7/cd197 polyclonal antibody, alexa fluor 647 conjugated - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
rabbit anti ccr7 cd197  (Bioss)
91
Bioss rabbit anti ccr7 cd197
Impaired chemotaxis of IL-6Rα KO BMDCs and its restoration by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. BMDCs were isolated from heterozygous (hetero) and IL-6Rα KO mice. A , Immunofluorescence of IL-6Rα in heterozygous (a) and IL-6Rα KO BMDCs (b) confirming the lack of IL-6Rα in KO BMDCs. B , Collagen-coated, modified Boyden chamber chemotaxis assays of heterozygous (hetero), IL-6Rα KO, and IL-6Rα KO in the presence of sIL-6Rα and IL-6 (KO+sIL-6R/IL-6). Note that KO BMDCs show reduced chemotaxis, which was rescued by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. C & D , IL-6Rα KO did not alter surface expression of <t>CCR7.</t> Immunofluorescence (C) showing similar levels of surface CCR7 in heterozygous (a) and IL-6Rα KO BMDCs (b). Flow cytometry analyses (D) confirming that IL-6Rα KO did not affect the levels of CCR7 surface expression. After CD86-positive heterozygous (a) and IL-6Rα KO (b) BMDCs were gated, the levels of CCR7 surface expression were examined in histogram (c).
Rabbit Anti Ccr7 Cd197, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti ccr7 cd197/product/Bioss
Average 91 stars, based on 1 article reviews
rabbit anti ccr7 cd197 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
mouse ccr7 polyclonal antibody  (Glaxo Smith)
90
Glaxo Smith mouse ccr7 polyclonal antibody
Impaired chemotaxis of IL-6Rα KO BMDCs and its restoration by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. BMDCs were isolated from heterozygous (hetero) and IL-6Rα KO mice. A , Immunofluorescence of IL-6Rα in heterozygous (a) and IL-6Rα KO BMDCs (b) confirming the lack of IL-6Rα in KO BMDCs. B , Collagen-coated, modified Boyden chamber chemotaxis assays of heterozygous (hetero), IL-6Rα KO, and IL-6Rα KO in the presence of sIL-6Rα and IL-6 (KO+sIL-6R/IL-6). Note that KO BMDCs show reduced chemotaxis, which was rescued by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. C & D , IL-6Rα KO did not alter surface expression of <t>CCR7.</t> Immunofluorescence (C) showing similar levels of surface CCR7 in heterozygous (a) and IL-6Rα KO BMDCs (b). Flow cytometry analyses (D) confirming that IL-6Rα KO did not affect the levels of CCR7 surface expression. After CD86-positive heterozygous (a) and IL-6Rα KO (b) BMDCs were gated, the levels of CCR7 surface expression were examined in histogram (c).
Mouse Ccr7 Polyclonal Antibody, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse ccr7 polyclonal antibody/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
mouse ccr7 polyclonal antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Impaired chemotaxis of IL-6Rα KO BMDCs and its restoration by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. BMDCs were isolated from heterozygous (hetero) and IL-6Rα KO mice. A , Immunofluorescence of IL-6Rα in heterozygous (a) and IL-6Rα KO BMDCs (b) confirming the lack of IL-6Rα in KO BMDCs. B , Collagen-coated, modified Boyden chamber chemotaxis assays of heterozygous (hetero), IL-6Rα KO, and IL-6Rα KO in the presence of sIL-6Rα and IL-6 (KO+sIL-6R/IL-6). Note that KO BMDCs show reduced chemotaxis, which was rescued by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. C & D , IL-6Rα KO did not alter surface expression of CCR7. Immunofluorescence (C) showing similar levels of surface CCR7 in heterozygous (a) and IL-6Rα KO BMDCs (b). Flow cytometry analyses (D) confirming that IL-6Rα KO did not affect the levels of CCR7 surface expression. After CD86-positive heterozygous (a) and IL-6Rα KO (b) BMDCs were gated, the levels of CCR7 surface expression were examined in histogram (c).

Journal: bioRxiv

Article Title: Investigation of fascin1, a marker of mature dendritic cells, reveals a New role for IL-6 signaling in chemotaxis

doi: 10.1101/2020.03.19.979104

Figure Lengend Snippet: Impaired chemotaxis of IL-6Rα KO BMDCs and its restoration by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. BMDCs were isolated from heterozygous (hetero) and IL-6Rα KO mice. A , Immunofluorescence of IL-6Rα in heterozygous (a) and IL-6Rα KO BMDCs (b) confirming the lack of IL-6Rα in KO BMDCs. B , Collagen-coated, modified Boyden chamber chemotaxis assays of heterozygous (hetero), IL-6Rα KO, and IL-6Rα KO in the presence of sIL-6Rα and IL-6 (KO+sIL-6R/IL-6). Note that KO BMDCs show reduced chemotaxis, which was rescued by the addition of soluble IL-6Rα (sIL-6Rα) and IL-6. C & D , IL-6Rα KO did not alter surface expression of CCR7. Immunofluorescence (C) showing similar levels of surface CCR7 in heterozygous (a) and IL-6Rα KO BMDCs (b). Flow cytometry analyses (D) confirming that IL-6Rα KO did not affect the levels of CCR7 surface expression. After CD86-positive heterozygous (a) and IL-6Rα KO (b) BMDCs were gated, the levels of CCR7 surface expression were examined in histogram (c).

Article Snippet: The primary antibodies used were: APC- (cat #,17-0862-81) and FITC-conjugated rat anti-CD86 (11-0862-81), AF647-labeled rat anti-mouse IL-6 (11-7061-81) and unconjugated rat anti-mouse CCR7 antibody (16-1971-85, clone 4B12, all from eBioscience, San Diego, CA); FITC-labeled MHC-II (107605), FITC-labeled CD80 (104705), and unconjugated anti-mouse IL-6Rα (115807, all from Biolegend, San Diego, CA); goat anti-mouse IL-6Rα (AF1830, R&D systems, Minneapolis, MN); rabbit anti-gp130 (sc-9045, Santa Cruz Biotech, Dallas, TX); and rabbit anti-CCR7 polyclonal antibody (TA310252, Origene, Rockville, MD).

Techniques: Chemotaxis Assay, Isolation, Immunofluorescence, Modification, Expressing, Flow Cytometry

IL-6Rα signaling is critical for CCR7 internalization and CCL19-induced ERK1/2 phosphorylation. A , Effects of the blockage of IL-6 signaling on CCR7 internalization. WT BMDCs were stimulated with CCL19 for 5 min in the presence of either control (a) or neutralizing antibody (b), and then surface CCR7 expression was determined by flow cytometry. Surface expression of CCR7 was examined with CD86 + BMDCs before (-CCL19) and after CCL19 addition (+CCL19). Note that CCR7 internalization was blocked in the absence of a neutralizing antibody to IL-6Rα. B , Effects of IL-6 signaling on CCR7 internalization of IL-6Rα KO BMDCs. IL-6Rα KO BMDCs were stimulated with CCL19 in the absence (a) or presence of sIL-6Rα (soluble IL-6Rα) and IL-6 (b). Note that IL-6Rα KO BMDCs showed impaired CCR7 internalization (a), which was rescued by the addition of sIL-6Rα and IL-6 (b). C , Inhibition of CCR7 internalization by the blockage of IL-6 signaling in HEK293T epithelial cells. HEK293T cells stably expressing mouse CCR7-GFP were stimulated with CCL19 in the presence of either control or neutralizing antibody against IL-6Rα. a-d, fluorescence images of CCR7-GFP in control cells (a & b) or IL-6Rα neutralizing antibody-treated cells (c & d) before (a & c) or after addition of CCL19 (b & d). The same cells were counter stained with an antibody specific to mouse CCR7 to detect only surface CCR7 (e-h) in control (e & f) or IL-6Rα neutralizing antibody-treated cells (g & h) before (e & g) or after (f & h) addition of CCL19. D , Quantitative measurements of surface CCR7 immunofluorescence (panels e-h of C) at cell-to-cell contacts. In contrast to the control, the addition of a neutralizing antibody against IL-6Rα blocked internalization of CCR7. E , Effects of the blockage of IL-6 signaling on CCL19-induced ERK1/2 phosphorylation of WT BMDCs. WT BMDCs were stimulated with CCL19 in the presence of a control or neutralizing antibody, then ERK1/2 phosphorylation levels were determined at 0, 5, 15 and 30min after CCL19 addition using Western blotting with a phosphospecific ERK1/2 antibody. For normalization, the same membranes were reblotted with a pan ERK1/2 antibody. The ratios of phosphoERK1/2 to total ERK1/2 are indicated below the figure.

Journal: bioRxiv

Article Title: Investigation of fascin1, a marker of mature dendritic cells, reveals a New role for IL-6 signaling in chemotaxis

doi: 10.1101/2020.03.19.979104

Figure Lengend Snippet: IL-6Rα signaling is critical for CCR7 internalization and CCL19-induced ERK1/2 phosphorylation. A , Effects of the blockage of IL-6 signaling on CCR7 internalization. WT BMDCs were stimulated with CCL19 for 5 min in the presence of either control (a) or neutralizing antibody (b), and then surface CCR7 expression was determined by flow cytometry. Surface expression of CCR7 was examined with CD86 + BMDCs before (-CCL19) and after CCL19 addition (+CCL19). Note that CCR7 internalization was blocked in the absence of a neutralizing antibody to IL-6Rα. B , Effects of IL-6 signaling on CCR7 internalization of IL-6Rα KO BMDCs. IL-6Rα KO BMDCs were stimulated with CCL19 in the absence (a) or presence of sIL-6Rα (soluble IL-6Rα) and IL-6 (b). Note that IL-6Rα KO BMDCs showed impaired CCR7 internalization (a), which was rescued by the addition of sIL-6Rα and IL-6 (b). C , Inhibition of CCR7 internalization by the blockage of IL-6 signaling in HEK293T epithelial cells. HEK293T cells stably expressing mouse CCR7-GFP were stimulated with CCL19 in the presence of either control or neutralizing antibody against IL-6Rα. a-d, fluorescence images of CCR7-GFP in control cells (a & b) or IL-6Rα neutralizing antibody-treated cells (c & d) before (a & c) or after addition of CCL19 (b & d). The same cells were counter stained with an antibody specific to mouse CCR7 to detect only surface CCR7 (e-h) in control (e & f) or IL-6Rα neutralizing antibody-treated cells (g & h) before (e & g) or after (f & h) addition of CCL19. D , Quantitative measurements of surface CCR7 immunofluorescence (panels e-h of C) at cell-to-cell contacts. In contrast to the control, the addition of a neutralizing antibody against IL-6Rα blocked internalization of CCR7. E , Effects of the blockage of IL-6 signaling on CCL19-induced ERK1/2 phosphorylation of WT BMDCs. WT BMDCs were stimulated with CCL19 in the presence of a control or neutralizing antibody, then ERK1/2 phosphorylation levels were determined at 0, 5, 15 and 30min after CCL19 addition using Western blotting with a phosphospecific ERK1/2 antibody. For normalization, the same membranes were reblotted with a pan ERK1/2 antibody. The ratios of phosphoERK1/2 to total ERK1/2 are indicated below the figure.

Article Snippet: The primary antibodies used were: APC- (cat #,17-0862-81) and FITC-conjugated rat anti-CD86 (11-0862-81), AF647-labeled rat anti-mouse IL-6 (11-7061-81) and unconjugated rat anti-mouse CCR7 antibody (16-1971-85, clone 4B12, all from eBioscience, San Diego, CA); FITC-labeled MHC-II (107605), FITC-labeled CD80 (104705), and unconjugated anti-mouse IL-6Rα (115807, all from Biolegend, San Diego, CA); goat anti-mouse IL-6Rα (AF1830, R&D systems, Minneapolis, MN); rabbit anti-gp130 (sc-9045, Santa Cruz Biotech, Dallas, TX); and rabbit anti-CCR7 polyclonal antibody (TA310252, Origene, Rockville, MD).

Techniques: Expressing, Flow Cytometry, Inhibition, Stable Transfection, Fluorescence, Staining, Immunofluorescence, Western Blot